Evidence map›Paper›PMID 2059661›Full record

ArticleCell regulation1991

Evidence that interleukin-1 and phorbol esters activate NF-kappa B by different pathways: role of protein kinase C.

K Bomsztyk, J W Rooney, T Iwasaki, N A Rachie, S K Dower, C H Sibley

Abstract read
In one paragraph

Article in Cell regulation, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 66 citations in OpenAlex.

  1. CMIP is a negative regulator of T cell signaling.Cellular & molecular immunology · 2020
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription.Proceedings of the National Academy of Sciences of the United States of America · 1991
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

K BomsztykDepartment of Medicine, University of Washington, Seattle 98195, USA.
J W Rooney
T Iwasaki
N A Rachie
S K Dower
C H Sibley
University of Washington · US

Funding

ROLE OF SYK KINASE AND CD22 IN B CELL ACTIVATIONP01GM042508 · NIGMS · UNIVERSITY OF WASHINGTON · PI LAW, CHE-LEUNG · 1989 to 1997
–
NIGMS NIH HHS GM-42508
6 · The paper itself

Abstract

Nuclear factor kappa B (NF-kappa B) is a ubiquitous transcription factor that affects expression of many genes, including immunoglobulin kappa (kappa), the interleukin-2 receptor alpha chain, and two genes in HIV-1. NF-kappa B can be activated by a number of stimuli, including pharmacological stimulation of protein kinase C by phorbol 12-myristate 13-acetate (PMA) and treatment in vitro with either protein kinase C or protein kinase A. This has lead to the proposal that these kinases are key enzymes in the physiological activation of NF-kappa B as well. We have used a murine B cell line, 70Z/3, and T cell line, EL-4 6.1 C10, to study the activation of NF-kappa B by two physiological activators, interleukin-1 alpha (IL-1) and lipopolysaccharide (LPS). There are four reasons to propose that these agents activate pathways that do not include protein kinase C as a major component in these cell lines. First, the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7) strongly inhibited PMA-induced activation of NF-kappa B in 70Z/3 cells but had no effect on NF-kappa B activated by IL-1 or LPS. Second, depletion of protein kinase C by prolonged growth of 70Z/3 in PMA abrogated the capacity of the cells to activate NF-kappa B in response to further PMA treatment. However, these same cells activated NF-kappa B normally after either IL-1 or LPS treatment. Third, IL-1 effectively activated NF-kappa B in EL-4 6.1 C10 cells, but PMA did not. Fourth, interferon-gamma is a potent activator of protein kinase C in 70Z/3 cells, but is completely inactive in the mobilization of NF-kappa B. These results suggest that the physiological inducers IL-1 and LPS activate NF-kappa B by pathways independent of protein kinase C in both 70Z/3 and EL-4 6.1 C10 cells.

Indexed as

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsBase SequenceCell LineDNAInterleukin-1IsoquinolinesLipopolysaccharidesMiceMolecular Sequence DataNF-kappa BPiperazinesProtein Kinase CTetradecanoylphorbol Acetate1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineDNAInterleukin-1IsoquinolinesLipopolysaccharidesNF-kappa BPiperazinesProtein Kinase CTetradecanoylphorbol Acetate

Identifiers

PMID2059661
PMCPMC361786
OpenAlexW1981353774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.